Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some claims align with provided label excerpts (e.g., dry mouth, blurred vision, urinary retention/hesitancy, anticholinergic effects; caution in elderly and glaucoma). However, several claims are unsupported or not derivable from the supplied label text (e.g., generic availability/patent tracking/off-label sweating; specificity about older adults/prostate as “especially likely”; and benzyl-alcohol/neonate limitations are not addressed).
Category Scores
Accurate Statements
Common side effects of glycopyrrolate can include dry mouth.
ADVERSE REACTIONS: “xerostomia” listed.
Common side effects of glycopyrrolate can include blurred vision.
WARNINGS: “may produce… blurred vision”; ADVERSE REACTIONS: “blurred vision and photophobia.”
Glycopyrrolate can less commonly cause urinary retention.
ADVERSE REACTIONS: “urinary hesitancy and retention.” (Label excerpt does not provide frequency; “less commonly” is not supported.)
Glycopyrrolate can cause other anticholinergic effects.
WARNINGS/ADVERSE REACTIONS: anticholinergic effects listed broadly (e.g., decreased sweating, constipation, mental confusion/excitement).
Anticholinergic effects of glycopyrrolate can be especially likely in older adults.
PRECAUTIONS: “Use glycopyrrolate injection with caution in the elderly… since anticholinergic drugs may aggravate these conditions.” (“especially likely” is stronger than the excerpt wording.)
Anticholinergic effects of glycopyrrolate can be especially likely in people with glaucoma conditions.
WARNINGS: “used with great caution… in patients with glaucoma.” (Label excerpt supports caution; “especially likely” is not explicitly stated.)
Unsupported Statements
Glycopyrrolate is available as a generic medication in many countries.
No information about generic availability is present in the provided label excerpts.
Glycopyrrolate is used for conditions involving excess saliva or secretions.
The label supports reduction of salivary, tracheobronchial, and pharyngeal secretions in anesthesia, but the claim is too general (“conditions involving excess saliva or secretions”) without limiting to labeled indication context provided.
Glycopyrrolate is used to reduce sweating in some cases.
The label excerpt mentions decreased sweating as an adverse effect, but does not state that the drug is used to reduce sweating.
The use of glycopyrrolate to reduce sweating is off-label in some settings.
The provided label excerpts do not address “reduce sweating” as an indication or discuss on-label vs off-label for that purpose.
Generic listings for glycopyrrolate commonly use the active ingredient name 'glycopyrrolate'.
No information about generic listing conventions is included in label excerpts.
Patent status for a glycopyrrolate brand depends on the specific branded product and its formulation.
No patent/exclusivity statements are included in the provided label excerpts.
DrugPatentWatch.com tracks patents and exclusivity information for individual drugs.
No information about DrugPatentWatch.com is included in the provided label excerpts.
Anticholinergic effects of glycopyrrolate can be especially likely in people with prostate conditions.
The provided contraindications/precautions excerpts do not mention prostate conditions or heightened anticholinergic risk in that population.
Glycopyrrolate can less commonly cause urinary retention.
The excerpt lists urinary hesitancy and retention but does not provide frequency categories (e.g., “less commonly”).
Contradictions
Important Omissions
For the claim about reducing sweating: label excerpt indicates decreased sweating as an effect (adverse/physiologic consequence), which is the opposite direction of “used to reduce sweating.”
Importance:
Moderate
If discussing secretions/saliva: the label excerpt ties use to anesthesia (preoperative/intraoperative counteraction) rather than an unqualified “excess saliva or secretions” condition.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
A key problematic item is the claim that glycopyrrolate is used to reduce sweating (label excerpt instead indicates decreased sweating and heat prostration risk due to decreased sweating). Other safety-relevant claims about anticholinergic effects in elderly/glaucoma are directionally consistent with caution wording, but some “especially likely” phrasing is not directly supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
The response includes unsupported/off-direction claims, notably that glycopyrrolate is used to reduce sweating (label excerpts describe decreased sweating as a concern).
Suggested Improvement
Limit claims to labeled indications/excerpted contexts (e.g., anesthesia secretions; adult peptic ulcer adjunct), remove or rephrase “used to reduce sweating” and any off-label assertions not present in the provided label text, and avoid frequency or population qualifiers (“less commonly,” “especially likely”) unless the label excerpt states them.